PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Linum Labs announces Molecule, a software platform and marketplace to accelerate innovation in pharma

Linum Labs, a software development studio that builds blockchain-based solutions, has announced Molecule, a market platform to accelerate innovation in the pharmaceutical and biotech industry.

Molecule connects scientists, patients, and industry in order to advance drug development in a collaborative open market. By creating an open market for participants to crowdfund and discover promising therapeutics, it aims to solve core issues in the industry’s current business and innovation model.

“The pharmaceutical industry faces an innovation crisis caused by the challenges around drug development and the monopolisation of IP,” says Paul Kohlhaas, CEO of Linum Labs. “Bringing a drug to market is a high-cost, high-risk, and slow endeavour, and it is generally large organisations that single-handedly shoulder these burdens, leading to unnecessarily high prices and a friction around innovation.”

“These large organisations also shelve any IP that is perceived to have less revenue potential or difficult and costly development paths. This has had a significant negative effect on innovation in the pharmaceutical industry, which has moved away from a high-risk pioneering approach. Instead, we have a low-risk high-ticket size environment where R&D is reduced and only ‘blockbuster drugs’ get approved for development, regardless of their potential impact on overall societal health and wellbeing.”

Molecule aims to transform the pharma industry by providing a platform for crowdsourcing funding and research, reducing risk for investors and IP creators while creating more diverse and inclusive treatments for patients and consumers.

Swiss-based Linum Labs AG began developing Molecule in early 2018 and intends to build out the platform as an open source industry initiative on behalf of the Molecule Foundation, a Swiss non-profit.

The next phase of development will include testing with an early user cohort and further iterations of the initial prototype, leading into a minimum viable product. This will be supported by a financing round due to start in Q2 2019.

The organisation is currently hiring and seeking interested parties to contribute towards an open source ecosystem accelerating innovation in drug development.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026